Novartis CEO tots up $10M in 2018, with top marks for innovation by Angus Liu Tuesday, February 12, 2019 Vas Narasimhan’s 2018 take-home pay suffered on bottom-of-the-barrel shareholder returns over three years, compared with its Big Pharma rivals.
Senators challenge Novartis' account of Cohen deal by Eric Sagonowsky Friday, July 13, 2018 Four Democratic senators have published a report rebutting Novartis' account of the details behind its consulting deal with Michael Cohen.
Scandal disrupts ex-Novartis CEO's move to hedge fund board: WSJ by Eric Sagonowsky Tuesday, May 22, 2018 Former Novartis CEO Joe Jimenez was set to join the board of a leading hedge fund, but the plans are now on hold, WSJ reports.
Novartis' top lawyer co-signed Cohen deal with ex-CEO Jimenez by Angus Liu Wednesday, May 16, 2018 Two people signed Novartis' contract with Michael Cohen, and now they've both left: Ex-CEO Joe Jimenez and GC Felix Ehrat, who stepped down Wednesday.
Novartis CEO reassures employees after 'mistake' of Cohen deal by Eric Palmer Friday, May 11, 2018 Novartis CEO Vas Narasimhan acknowledged the company “made a mistake” by striking a $1.2 million deal with Trump lawyer Michael Cohen.
Novartis CEO says he’s committed to ethics. So prove it—Editor’s Corner by Tracy Staton Thursday, May 10, 2018 After round-the-world scandals, it certainly appears Novartis has a systemic problem. But Vas Narasimhan has a clean slate—and he needs to use it.
What we still don't know about the Novartis-Cohen relationship by Angus Liu, Eric Sagonowsky Thursday, May 10, 2018 Novartis' account of the Michael Cohen deal leaves plenty of unanswered questions.
Novartis insiders say Cohen sold ex-CEO access to Trump by Tracy Staton Thursday, May 10, 2018 Novartis insiders blame ex-CEO Joe Jimenez for a $1.2M contract with Trump attorney Michael Cohen—and they say Novartis was buying access, not advice.
Novartis inks digital deal to create prescription software by Tracy Staton Thursday, March 1, 2018 Putting digital into Novartis' DNA is one of CEO Vas Narasimhan’s goals, and the drugmaker has just inked another deal that aims to do just that.
New Novartis chief Narasimhan sees growth, but risks, ahead by Tracy Staton Wednesday, January 24, 2018 Incoming Novartis chief Vas Narasimhan outlined his big goals as CEO on Wednesday: Think drug launches and more drug launches.
